GE Healthcare Life Sciences completes transition into Cytiva
Apr 1, 2020 · In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation decided to spend $21.4bn (€19.5bn) to acquire GE Healthcare Life Sciences .. Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva.
US pharma hubs: The rising stars to watch
May 4, 2022 · CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.
BMS buys Orum Therapeutics’ ADC protein degrader for up to …
Nov 6, 2023 · The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
Donaldson Company acquires bioprocessing equipment company …
Nov 23, 2021 · Donaldson Company, Inc., a global provider of filtration products and solutions, has acquired Solaris Biotechnology Srl for around €41m ($46m).
Vertex and CRISPR Therapeutics advance towards EMA approval …
Jan 26, 2023 · In August 2022, the US Food and Drug Administration (FDA) approved bluebird bio’s Zynteglo, a gene therapy for beta-thalassemia, marking the first US approval for a lentiviral vector. While Zynteglo was given the green light in Europe in 2019, the company took the drug off the market as part of its withdrawal from the region after failing to reach agreements with governments over coverage ...
GPB Scientific becomes Curate Biosciences
Feb 10, 2022 · The company has spent six years working on a platform focused on cell potency and recovery; it says it has cracked one of the biggest problems in cell therapy: extracting enough potent cells to treat chronically sick patients.
Jade Biosciences raises $80M for autoimmune disease therapies
Aug 6, 2024 · Jade Biosciences has announced the closing of a $80 million funding round led by Fairmount and Venrock Healthcare Capital Partners, and with the participation of Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP.
Biosimilar producer looking to get first to market advantage in …
Jun 23, 2021 · Bio-Thera Solutions recently initiated a Phase 3 trial of its proposed golimumab biosimilar BAT2506 in China and Eastern Europe, making it the first subcutaneous golimumab biosimilar to do so in multiple countries, according to a report from GlobalData.
BioNTech and Crescendo Biologics team up to develop multi …
Jan 11, 2022 · Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody therapeutics. Its lead proprietary candidate is CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumor-specific T cells exclusively within the tumor microenvironment.
Sygnature Discovery acquires NuChem Sciences
Aug 3, 2023 · According to Sygnature, this acquisition create a ‘significant competitive advantage’ for the biotech firm as it expands its global footprint and business operations with discovery expertise in the North American market.